Tg Therapeutics (TGTX) Revenue (2017 - 2026)

Tg Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $204.9 million for Q1 2026.

• On a quarterly basis, Revenue rose 69.56% year-over-year to $204.9 million in Q1 2026; TTM through Mar 2026 was $700.3 million, a 81.26% increase from a year earlier, with the FY2025 full-year figure at $616.3 million, up 87.32% from the prior year.
• Revenue grew to $204.9 million in Q1 2026 per TGTX's latest filing, from $192.6 million in the prior quarter.
• Across five years, Revenue topped out at $204.9 million in Q1 2026 and bottomed at $80000.0 in Q4 2022.
• The 5-year median for Revenue is $73.5 million (2024), against an average of $81.6 million.
• Across the five-year window, Revenue sank 96.55% in 2022 and surged 176298.94% in 2023, its largest moves.
• Year by year, Revenue stood at $80000.0 in 2022, then surged by 54863.75% to $44.0 million in 2023, then surged by 146.04% to $108.2 million in 2024, then jumped by 78.0% to $192.6 million in 2025, then grew by 6.41% to $204.9 million in 2026.
• Per Business Quant, the three latest TGTX Revenue figures stand at $204.9 million (Q1 2026), $192.6 million (Q4 2025), and $161.7 million (Q3 2025).